Invitation to audiocast for Devyser’s Q3 Report 2022

On Thursday November 10, at 08.30 CET, Devyser Diagnostics AB will host an online presentation of its Q3 2022 interim report (which will have been published earlier on November 10, at 07.30 CET). The presentation will be held in English. 

This call will be an audiocast only and questions can be emailed to fredrik.alpsten@devyser.com in advance or during the call and will be answered at the end of the presentation.

The presentation will be webcast and can be accessed from the following web address: 

https://ir.financialhearings.com/devyser-diagnostics-q3-2022

Speakers: CEO Fredrik Alpsten, CFO Sabina Berlin and founder and Deputy CEO Ulf Klangby

The information was submitted for publication, through the agency of the contact persons below, on November 2, 2022 at 11:00 CET.

For more information, please contact:

Fredrik Alpsten, CEO
E-mail: fredrik.alpsten@devyser.com
Tel: +46 706 673 106

Sabina Berlin, CFO
E-mail: sabina.berlin@devyser.com
Tel: +46 739 519 502

About Devyser Diagnostics AB (publ)

Devyser develops, produces, and sells genetic testing kits to laboratories in more than 45 countries. The products are used for advanced DNA testing in the hereditary disease, oncology, and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient monitoring. Devyser’s products simplify complex genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. The company was founded in 2004 and is based in Stockholm, Sweden.

Devyser’s shares are listed on the Nasdaq First North Growth Market Stockholm (ticker: DVYSR). The company’s Certified Adviser is Redeye AB. For more information, visit www.devyser.com.